Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1964 2
1965 1
1975 2
1977 2
1978 1
1979 1
1980 3
1981 4
1982 9
1983 8
1984 7
1985 12
1986 12
1987 18
1988 17
1989 23
1990 23
1991 18
1992 25
1993 15
1994 21
1995 13
1996 18
1997 18
1998 20
1999 11
2000 15
2001 11
2002 15
2003 11
2004 19
2005 19
2006 19
2007 36
2008 43
2009 41
2010 41
2011 55
2012 61
2013 85
2014 86
2015 94
2016 100
2017 95
2018 102
2019 131
2020 123
2021 155
2022 155
2023 153
2024 59

Text availability

Article attribute

Article type

Publication date

Search Results

1,825 results

Results by year

Filters applied: . Clear all
Page 1
Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy.
Wang H, Liu B, Wei J. Wang H, et al. Cancer Lett. 2021 Oct 1;517:96-104. doi: 10.1016/j.canlet.2021.06.008. Epub 2021 Jun 12. Cancer Lett. 2021. PMID: 34129878 Review.
Accumulating evidence has shown that alterations of B2M gene and B2M proteins contribute to poor reaction to cancer immunotherapies by dampening antigen presentation. ...Furthermore, we summarize some promising therapeutic strategies to improve the efficacy inhibite …
Accumulating evidence has shown that alterations of B2M gene and B2M proteins contribute to poor reaction to cancer immunother …
Whole blood ACTB, B2M and GAPDH expression reflects activity of inflammatory bowel disease, advancement of colorectal cancer, and correlates with circulating inflammatory and angiogenic factors: Relevance for real-time quantitative PCR.
Bednarz-Misa I, Neubauer K, Zacharska E, Kapturkiewicz B, Krzystek-Korpacka M. Bednarz-Misa I, et al. Adv Clin Exp Med. 2020 May;29(5):547-556. doi: 10.17219/acem/118845. Adv Clin Exp Med. 2020. PMID: 32424999 Free article.
RESULTS: HPRT1, SDHA and TBP were superior normalizers in CRC and IBD. The highest expression variability was noted in active IBD. B2M was significantly lower in CRC but higher in IBD. GAPDH was higher in CRC and IBD. ...CONCLUSIONS: Leukocyte GAPDH, ACTB, and B2M e …
RESULTS: HPRT1, SDHA and TBP were superior normalizers in CRC and IBD. The highest expression variability was noted in active IBD. B2M …
Antitumor Immune Responses in B2M-Deficient Cancers.
Torrejon DY, Galvez M, Abril-Rodriguez G, Campbell KM, Medina E, Vega-Crespo A, Kalbasi A, Comin-Anduix B, Ribas A. Torrejon DY, et al. Cancer Immunol Res. 2023 Dec 1;11(12):1642-1655. doi: 10.1158/2326-6066.CIR-23-0139. Cancer Immunol Res. 2023. PMID: 37801341
beta2-microglobulin (B2M) is a critical component of the MHC class I molecule and is required to present tumor antigens to T cells. ...The more aggressive B16 without B2M expression only partially responded to the IL2 agonist, and this was dependent on NK cells. ...
beta2-microglobulin (B2M) is a critical component of the MHC class I molecule and is required to present tumor antigens to T cells. . …
Cell Surface B2m-Free Human Leukocyte Antigen (HLA) Monomers and Dimers: Are They Neo-HLA Class and Proto-HLA?
Ravindranath MH, Ravindranath NM, Selvan SR, Hilali FE, Amato-Menker CJ, Filippone EJ. Ravindranath MH, et al. Biomolecules. 2023 Jul 28;13(8):1178. doi: 10.3390/biom13081178. Biomolecules. 2023. PMID: 37627243 Free PMC article. Review.
Cell surface HLA-I molecules (Face-1) consist of a polypeptide heavy chain (HC) with two groove domains (G domain) and one constant domain (C-domain) as well as a light chain, B2-microglobulin (B2m). However, HCs can also independently emerge unfolded on the cell surface w …
Cell surface HLA-I molecules (Face-1) consist of a polypeptide heavy chain (HC) with two groove domains (G domain) and one constant domain ( …
β2-microglobulin functions as an endogenous NMDAR antagonist to impair synaptic function.
Gao Y, Hong Y, Huang L, Zheng S, Zhang H, Wang S, Yao Y, Zhao Y, Zhu L, Xu Q, Chai X, Zeng Y, Zeng Y, Zheng L, Zhou Y, Luo H, Zhang X, Zhang H, Zhou Y, Fu G, Sun H, Huang TY, Zheng Q, Xu H, Wang X. Gao Y, et al. Cell. 2023 Mar 2;186(5):1026-1038.e20. doi: 10.1016/j.cell.2023.01.021. Cell. 2023. PMID: 36868208
Moreover, genetic ablation of B2m or systemic administration of an anti-B2M antibody counteracts synaptic impairments in DS mice. ...Our findings identify B2M as an endogenous NMDAR antagonist and reveal a pathophysiological role for circulating B2M in …
Moreover, genetic ablation of B2m or systemic administration of an anti-B2M antibody counteracts synaptic impairments in DS mi …
B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy.
Zhang C, Li D, Xiao B, Zhou C, Jiang W, Tang J, Li Y, Zhang R, Han K, Hou Z, Zhang L, Sui Q, Liao L, Pan Z, Zhang X, Ding P. Zhang C, et al. J Immunother. 2022 May 1;45(4):187-193. doi: 10.1097/CJI.0000000000000417. J Immunother. 2022. PMID: 35343934 Free PMC article.
Compared with B2M wild-type CRCs, B2M-mutated CRCs did not show a higher frequency of resistance to anti-PD-1 therapy (P=0.71). ...B2M and JAK1/2 loss-of-function mutations occur frequently in microsatellite instability-high CRC. ...
Compared with B2M wild-type CRCs, B2M-mutated CRCs did not show a higher frequency of resistance to anti-PD-1 therapy (P=0.71) …
B2M overexpression correlates with malignancy and immune signatures in human gliomas.
Zhang H, Cui B, Zhou Y, Wang X, Wu W, Wang Z, Dai Z, Cheng Q, Yang K. Zhang H, et al. Sci Rep. 2021 Mar 3;11(1):5045. doi: 10.1038/s41598-021-84465-6. Sci Rep. 2021. PMID: 33658560 Free PMC article.
B2M also suppressed anti-tumor immunity through immune related processes. ...Finally, functional annotation of the identified B2M related genes verified that B2M was a potential candidate for immunotherapy. ...
B2M also suppressed anti-tumor immunity through immune related processes. ...Finally, functional annotation of the identified B2M …
β2-Microglobulin Maintains Glioblastoma Stem Cells and Induces M2-like Polarization of Tumor-Associated Macrophages.
Li D, Zhang Q, Li L, Chen K, Yang J, Dixit D, Gimple RC, Ci S, Lu C, Hu L, Gao J, Shan D, Li Y, Zhang J, Shi Z, Gu D, Yuan W, Wu Q, Yang K, Zhao L, Qiu Z, Lv D, Gao W, Yang H, Lin F, Wang Q, Man J, Li C, Tao W, Agnihotri S, Qian X, Shi Y, You Y, Zhang N, Rich JN, Wang X. Li D, et al. Cancer Res. 2022 Sep 16;82(18):3321-3334. doi: 10.1158/0008-5472.CAN-22-0507. Cancer Res. 2022. PMID: 35841593
Inhibition of B2M attenuated GSC survival, self-renewal, and tumor growth. B2M-induced TGFbeta1 secretion activated paracrine SMAD and PI3K/AKT signaling in TAMs and promoted an M2-like macrophage phenotype. These findings reveal tumor-promoting functions of B2M …
Inhibition of B2M attenuated GSC survival, self-renewal, and tumor growth. B2M-induced TGFbeta1 secretion activated paracrine …
B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy.
Zhao Y, Cao Y, Chen Y, Wu L, Hang H, Jiang C, Zhou X. Zhao Y, et al. Immunology. 2021 Nov;164(3):507-523. doi: 10.1111/imm.13384. Epub 2021 Jun 21. Immunology. 2021. PMID: 34115389 Free PMC article.
In syngeneic mouse models, genetic ablation of B2M in tumour cells causes resistance to PD-1-based immunotherapy, and B2M knockdown also diminishes the therapeutic efficacy. Moreover, forced expression of B2M in tumour models improves the response to immunoth …
In syngeneic mouse models, genetic ablation of B2M in tumour cells causes resistance to PD-1-based immunotherapy, and B2M knoc …
B2M mutation paves the way for immune tolerance in pathogenesis of Epstein-Barr virus positive diffuse large B-cell lymphomas.
He M, Liu B, Tang G, Jiao L, Liu X, Yin S, Wang T, Chen J, Gao L, Ni X, Wang L, Xu L, Yang J. He M, et al. J Cancer. 2022 Nov 7;13(15):3615-3622. doi: 10.7150/jca.75813. eCollection 2022. J Cancer. 2022. PMID: 36606194 Free PMC article.
Results revealed that most gene mutations were not specific for EBV positive DLBCL. However, B2M (beta2-microglobulin) mutations were significantly increased and HLA-I or HLA-II expression was decreased in these cases, which was related to patient's poor outcome. B2M …
Results revealed that most gene mutations were not specific for EBV positive DLBCL. However, B2M (beta2-microglobulin) mutations were …
1,825 results